Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)-Reference-Cited by-同舟云学术

Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)

Published:2020-08-26 Issue:S2 Volume:41 Page:487-488
ISSN:1590-1874
Container-title:Neurological Sciences
language:en
Short-container-title:Neurol Sci

Author:

Vernieri Fabrizio,Altamura Claudia,Aurilia Cinzia,Brunelli Nicoletta,Egeo Gabriella,Fofi Luisa,Costa Carmelina Maria,Fallacara Adriana,Favoni Valentina,Pierangeli Giulia,Aguggia Marco,Bertuzzo Davide,Albanese Maria,Di Fiore Paola,Frediani Fabio,Cevoli Sabina,Barbanti Piero

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Clinical Neurology,Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10072-020-04669-y.pdf

Reference3 articles.

1. Stauffer VL, Dodick DW, Zhang Q et al (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080–1088. https://doi.org/10.1001/jamaneurol.2018.1212

2. Skljarevski V, Matharu M, Millen BA et al (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442–1454. https://doi.org/10.1177/0333102418779543

3. Detke HC, Goadsby PJ, Wang S et al (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211–e2221. https://doi.org/10.1212/WNL.0000000000006640

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study;Pain and Therapy;2024-03-28

2. Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review;The Journal of Headache and Pain;2023-06-22

3. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients;The Journal of Headache and Pain;2023-06-02

4. Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment;Journal of Clinical Medicine;2023-05-21

5. Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine;Neurology International;2023-02-13